Evidence map›Paper›PMID 30973876›Full record

ArticlePLoS neglected tropical diseases2019

Broken drug markets in infectious diseases: Opportunities outside the private sector?

Jonathan D Alpern, Stephen J Dunlop, William M Stauffer

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan D AlpernDivision of Infectious Diseases, Department of Medicine, HealthPartners, Minneapolis, Minnesota, United States of America.ORCID 0000-0001-8514-8693
Stephen J DunlopDepartment of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, United States of America.
William M StaufferDivision of Infectious Diseases, Department of Medicine, HealthPartners, Minneapolis, Minnesota, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution.

Indexed as

Anti-Infective AgentsCommunicable DiseasesDrug IndustryDrugs, GenericHumansPrescription DrugsPublic SectorUnited StatesUnited States Food and Drug AdministrationAnti-Infective AgentsDrugs, GenericPrescription Drugs

Identifiers

PMID30973876
PMCPMC6459471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.